Article

Synergistic cytotoxicity with Chk1/Chk2-inhibitor prexasertib in small cell lung cancer following lurbinectedin-induced G2/M-checkpoint activation

2026-08-04

Abstract excerpt

Small cell lung cancer (SCLC) is an aggressive thoracic malignancy with a 5-year survival rate under 7%. Lack of meaningful improvement of survival rates despite advances in treatment highlights the need for novel therapeutic approaches to improve patient outcomes. Currently, carboplatin + etoposide chemotherapy is the backbone of treatment for most patients. Lurbinectedin is a cytotoxic drug with unique activity...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 7abe3bf5-ce8a-5515-9f30-666ea522629a
DOI: 10.64898/2026.08.02.742299

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Synergistic cytotoxicity with Chk1/Chk2-inhibitor prexasertib in small cell lung cancer following lurbinectedin-induced G2/M-checkpoint activationDOI 10.64898/2026.08.02.742299Read

Signature-driven repurposing of Midostaurin for combination with MEK1/2 and KRASG12C inhibitors in lung cancer.Semantic proximity Read

Acquired small cell lung cancer resistance to Chk1 inhibitors involves Wee1 up‐regulationSemantic proximity Read

BRCA1 orchestrates the response to BI-2536 and its combination with alisertib in MYC-driven small cell lung cancerSemantic proximity Read

BET-Inhibitor I-BET762 and PARP-Inhibitor Talazoparib Synergy in Small Cell Lung Cancer CellsSemantic proximity Read

Targeting a non-oncogene addiction to the ATR/CHK1 axis for the treatment of small cell lung cancerSemantic proximity Read

CHK1 levels correlate with sensitization to pemetrexed by CHK1 inhibitors in non-small cell lung cancer cells.Semantic proximity Read

Unveiling the Mechanism of Lurbinectedin’s Action and Its Potential in Combination Therapies in Small Cell Lung CancerSemantic proximity Read

SIGNATURE-DRIVEN REPURPOSING OF MIDOSTAURIN FOR COMBINATION WITH MEK1/2 AND KRASG12C INHIBITORS IN LUNG CANCERSemantic proximity Read

Treatment with the Chk1 inhibitor Gï¿½6976 enhances cisplatin cytotoxicity in SCLC cellsSemantic proximity Read

DNA-PK inhibition sustains the antitumor innate immune response in small cell lung cancerSemantic proximity Read

NSCLC cells demonstrate differential mode of cell death in response to the combined treatment of radiation and a DNA-PKcs inhibitorSemantic proximity Read

Targeting WEE1 enhances the antitumor effect of KRAS-mutated non-small cell lung cancer harboring TP53 mutations.Semantic proximity Read